KB-1169

Ramucirumab

Background

Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2, a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Through blocking activation of VEGFR-2 by VEGF-A and the other VEGF ligands, ramucirumab inhibits the angiogenesis pathways involved in the development and progression of gastric cancer.

Specifications

Catalog Number:
KB-1169
Cell Line Name:
Ramucirumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
VEGFR2
Species Reactivity:
Human
Application:
FACS | FACS Blocking
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | FACS | FACS Blocking

References

1.Cyramza (ramucirumab) package insert. Eli Lilly and Company. 2014 Retrieved from https://www.cyramza.com. Wadhwa Roopma, Taketa Takashi, Sudo Kazuki, Blum-Murphy Mariela, Ajani Jaffer A. Ramucirumab: a novel antiangiogenic agent. Future Oncology (London, England) 2013;9:789–795
Please enable JavaScript in your browser to complete this form.